추천자료
20세기의 얼굴 레포트
[경영전략] 아그로수퍼 성공전략 분석
[에이즈][후천성면역결핍증][AIDS]에이즈(후천성면역결핍증,AIDS)발견,감염경로,발생현황, 에이즈(후천성면역결핍증,AIDS)진단,예방전략
[AIDS][후천성면역결핍증][에이즈]AIDS(후천성면역결핍증, 에이즈)의 의미,실태,발병단계,감염경로,검사방법,치료제개발,감염사례,예방전략
SEN Amartya 저서 Human security now Commission on Human Security 번역과제 Huma
인간안보 연구보고서
[보건소 방문 및 실습 조사, 실태조사] 보건소 개념, 역할, 현황, 문제점 및 실태 / 개선방안 및 해결방안
[관광] 인도의료관광
사회과학 새천년개발목표
UN 지속가능 개발목표_환경오염 및 개선방안
소개글
[의료패러다임] HIV와 AIDS의 전염병 통제를 위한 분석과 대책(영문)에 대한 자료입니다.
목차
Introduction
Access to treatment
Critical challenges to HIV
New projections on HIV incidence
Effective Prevention Interventions
Inadequate current access to prevention
Addressing factors that increaseVulnerability to infection
Annual number of new HIV infections in Thailand 1985-2003
Emerging prevention successes?
Common elements of successful national efforts
본문내용
Adherence rate of therapy : Sub-Saharan Africa > North America
->why? Easy to be more alerted in SS Africa. Especially visitors.
But Sustained treatment puts AIDS into chronic state
-> this kind of side effect will decrease overtime.
* DART trial (in uganda)
-Entebbe cohort: untreated control group
-> dramatic impact on survival rate
Upon antiretroviral therapy
1981-1992 : before the antiviral era
1996 : antiviral therapy actually began
-> much better response as the times go by.
Only about 25% of those in need of treatment currently receive it in the developing world.
Less than half of infected persons are eligible for treatment based on current guidelines(only eligible at advanced stages of diseases)
Treatment must be administered for lifetime and does not cure infection
Treatment regimens are complex, toxic, and expensive.
For every new person started on treatment in 2006, approximately 6 new infections occurred.
Sexual transmission
Abstinence, reduced sexual partners
Condoms- 80-90% protection with proper&consistent use
Male circumcision- 50-60% reduction in female to male transmission
Control sexually transmitted infections – reduce co-factors that facilitate transmission
Contaminated blood/needle exposure
IDU – reduce needle sharing, needle exchange programs, drug substitution programs
Screening of transfused blood products
Health care settings – universal precautions, post-exposure prophylaxis